Diana Ernst, RPh

Several changes have been made to the adult immunization schedule 2023.

The BLA is supported by a comprehensive data package that includes data from the phase 1/3 ROSALIA study.

Recent data show that the product is unlikely to be active against currently circulating SARS-CoV-2 variants.

Results showed vaccine efficacy of 83.7% against RSV-LRTD, defined by 2 or more symptoms.

The preliminary safety signal was identified by the CDC’s Vaccine Safety Datalink.

Based on the information presented at the meeting, the FDA will make a decision on the best course of action regarding adjustments to current authorizations and approvals.

The AAP has released a new list of 5 tests and procedures commonly ordered in pediatric emergency medicine that physicians and patients should question.

Immune responses after Priorix administration were noninferior to those observed with M-M-R II.

The recommendations were give a “D” grade indicating that there is moderate or high certainty that the harms associated with hormone therapy use in these settings outweigh any potential benefits.

Molnupiravir is a nucleoside analogue that inhibits SARS-CoV-2 replication by viral mutagenesis.

The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.